• Partners Theravance and Mylin Submit New Drug Application for Revefenacin as COPD Treatment
  • Boehringer Ingelheim to Host Live Event on Facebook, Twitter for Nov. 15, World COPD Day
  • Enrollment for Phase 2b Trial of Verona’s COPD Therapy RPL554 Is Ahead of Schedule
  • Anoro Ellipta Outperforms Stiolto Respimat in Improving Lung Function, Study Finds
  • Pivotal Phase 3 Trials Demonstrate SUN-101/eFlow is Safe, Effective, Analyses Show
  • COPD Foundation, Geisinger, GSK, and Jvion Join Forces in Machine Learning Initiative
  • New COPD Treament Option, Seebri Neohaler, Now Available to U.S. Patients
  • E-cigarettes are Poor Substitutes for Conventional Smoking in COPD Patients
  • Researchers Identify Grape Polyphenol that May Suppress COPD Lung Inflammation
  • AIRWISE Phase 4 Trial Assessing Various Combos of COPD Therapies Is Underway
  • Bevespi Aerosphere Progressing Toward Regulatory Approval for COPD in Europe, Asia
  • Stem Cells May Offset Damage Done by Smoking to Cells in Lungs, Early Study Says